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Abstract
Objectives: This retrospective study reassessed nasopharyngeal carcinoma (NPC) patients treated with
intensity-modulated radiation therapy (IMRT), to determine the significance how magnetic resonance imaging
(MRI)-derived masticator space involvement (MSI) affected patients’ prognosis.
Methods: One thousand one hundred ninety seven NPC patients who had complete set of MRI and medical records
were enrolled. Basing on their MRI findings, the T-categories of tumors were identified according to the seventh
edition of American Joint Committee on Cancer staging system, which considers MSI a prognostic indicator for NPCs.
Rates of overall survival (OS), local relapse-free survival (LRFS), regional relapse-free survival (RRFS) and distant
metastasis-free survival (DMFS) were analyzed by the Kaplan-Meier method, and the Log-Rank test compared their
differences. Cox regression analysis was employed to evaluate various prognostic factors systematically. Statistical
analyses were conducted with SPSS 18.0 software, P value < 0.05 was considered statistically significant.
Results: Medial pterygoid muscle (MPM) was involved in 283 (23.64 %) cases, of which lateral pterygoid muscle
(LPM) was concurrently affected in 181 (15.12 %) and infratemporal fossa (ITF) in 19 (1.59 %). Generally, MSI
correlated with an OS, LRFS, and DMFS consistent with a T4-stage diagnosis (P > 0.05). Although different degrees
of MSI presented a similar OS and DMFS (P > 0.1), tumors involving LPM had a relatively poorer LRFS than those
affected the MPM only (P = 0.027), even for subgroup of patients composed of T3 and T4 classifications (P = 0.035).
A tumor involving MPM brought an LRFS consistent with a T2 or T3-stage disease (P > 0.1). If the tumor affected
LPM or ITF concurrently, the survival outcomes were more consistent with a T4-stage disease (P > 0.1). Nevertheless,
compared to tumor infiltrating MPM, those invading LPM or ITF more frequently spread into other concurrent sites
that earned higher T-staging categories. Moreover, multivariate analyses indicated the degree of MSI was a significant
prognostic factor for the OS of NPCs (P = 0.036).
Conclusions: Degree of MSI is a significant prognosticator for the OS of IMRT-treated NPCs, and the prognosis of
patients with lateral MSI extension (LPM and ITF) were shown to be significantly worse than those affected only MPM
or the T3-stage disease. Thus, it is highly recommended that lateral MSI extension be a higher T-staging category.
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Background
Nasopharyngeal carcinoma (NPC) arises from nasopha-
ryngeal mucosa, and presents an invasive biological
behavior that is prone to infiltrate the surrounding struc-
tures, especially those lying laterally in parapharyngeal
space, masticator space (MS), and infratemporal fossa
(ITF) [1]. NPC is known to be a radiosensitive tumor type,
and chemoradiotherapy (CRT) is the primary treatment
modality [2–4]. Reported 5-year overall survival (OS) rates
for NPC patients have ranged from 58.6 to 83 %, and pre-
treatment tumor-node-metastasis (TNM) staging is used
to guide assessments of the patient’s prognosis [5–8].
However, the T-categories and prognostic value of NPCs
with a tumor involving MS are controversial [9–11].
MS is an intact anatomical space that contains the
masticatory muscles, the posterior body and ramus of
the mandible, and the mandibular division of the trigem-
inal nerve (V3). Reports of the frequency of masticator
space involvement (MSI) in NPC have varied widely,
ranging from 19.7 to 61 % [9–11]. Since most studies
emphasized that MSI was one of the significant prognos-
tic factors for NPC patients [9, 11], the American Joint
Committee on Cancer (AJCC) staging system and the
Chinese staging system that was revised in 2008 both
recommended MSI as an independent factor for the
T-stage classifications of NPC. However, a complicat-
ing matter is the fact that standards for T-staging cat-
egories, as set by the 2008 Chinese staging system,
differed from those of AJCC [12]. Moreover, the
AJCC changed its guidelines in the most recent edi-
tion (seventh edition) [13], and now considers the MS
to be composed of a medial part (contains the medial
pterygoid muscle [MPM] and lateral pterygoid muscle
[LPM]) and a lateral part (contains the temporal and
masseter muscle). This is a departure from the fifth
and sixth editions that defined tumors with MSI as only
affecting the lateral part of anatomical MS (also termed
“infratemporal fossa [ITF]”), and categorized them as T4
disease. In the seventh edition, however, tumors involving
the medial or lateral part (or both) are categorized as T4
disease [12, 13]. On the other hand, the 2008 Chinese sta-
ging system categorizes tumors involving the MPM only
as T3 tumors, and those concurrently infiltrating other
masticatory muscles are categorized as T4 tumors. Given
these inconsistencies, it is imperative to build a consensus
on the standards for T-staging categories of NPC with
MSI. Besides, most previous studies assessed the progno-
sis of MSI in NPCs treated with conventional radiotherapy
or mixed with intensity-modulated radiation therapy
(IMRT). Nowadays, however, IMRT is extensively treated
as the standard radiotherapy technique for NPC [14–16]
and obtains an excellent local control rate, even for those
with locally advanced diseases (i.e., T3 or T4 classifica-
tions) [8, 15]. Nevertheless, the prognostic value of MSI in
NPCs treated with IMRT has not yet been accurately
assessed.
Certain anatomical characteristics make it difficult to
assess MSI through clinical examinations alone, so im-
aging modalities are essential to evaluate this region
more efficiently [17–19]. Previously, computed tomog-
raphy (CT) was valuable in the pretreatment TNM sta-
ging for NPC, especially in determining the T-staging
categories. Compared to CT, whereas, magnetic reson-
ance imaging (MRI) can provide a better tissue contrast
and a multiplanar capability [18–20], which allows for a
more accurate evaluation of the primary nasopharynx
tumor’s extension into adjacent structures, in particular
the MS or ITF. For these reasons, both the AJCC and
the 2008 Chinese staging systems recommend MRI as
the optimal imaging modality for T- and N-staging in
newly diagnosed NPC [12, 13]. Accordingly, King et al.
have demonstrated the more excellent diagnostic power of
MRI with a sensitivity, specificity, and accuracy of 100, 93,
and 95 %, respectively, when compared to endoscopy
[20, 21]. Indeed, routine MRI with T2-weighted fast spin-
echo and contrast-enhanced T1-weighted images in axial
and coronal planes can clearly determine whether a tumor
has spread into the MS and/or ITF [19].
Taking these advances of MRI into consideration, we
retrospectively re-evaluated a cohort of consecutive
newly diagnosed NPC patients who had been treated
with IMRT and also had complete MRI images, medical
records, and follow-up data in order to accurately as-
sess whether MSI should influence the porgnoses and
T-staging category of NPCs.
Methods
Ethics statements
This retrospective study was approved by the Institutional
Review Board of Fujian Provincial Cancer Hospital &
Institute (No. 200908). Permission was given to conduct
this retrospective study without obtaining informed con-
sent. All information was anonymized and de-identified
prior to analysis.
Patient selection and pretreatment evaluation
Data were collected from 1241 consecutive and newly
diagnosed NPC patients who were clear of any distant
organ metastasis. All patients had been resorted to and
treated with IMRT at the Fujian Provincial Cancer
Hospital & Institute between July 2005 and December
2011. Of the 1241 cases, 44 did not have a pretreatment
MRI and so were excluded from this study. The
remaining 1197 cases with complete MRI data were
recruited, who were histopathologically confirmed as
having NPC via analysis of a naso-pharyngoscopy biopsy.
Based on their MRI findings, we staged all patients
according to the criteria of the seventh edition of the
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AJCC staging system [13]. Table 1 summarized the clin-
ical characteristics of enrolled patients.
Treatment regimens
All patients were initially treated with definitive IMRT.
The mean dose of radiotherapy was 70.35 Gy (range
from 61.6 Gy to 86.65 Gy), and the mean fraction was
31.5 (range from 28 to 49) with a 2.25 Gy per fraction. A
detailed description of the IMRT has been published
previously [15, 22]. A total of 1029 patients (85.96 %) re-
ceived platinum-based chemotherapy, as follows (see
Table 1): induction in 253 (21.14 %), concurrent in 71
(5.93 %), adjuvant in 16 (1.34 %), induction-concurrent
in 212 (17.71 %), induction-adjuvant in 294 (24.56 %),
concurrent-adjuvant in 23 (1.92 %), and induction-
concurrent-adjuvant in 160 (13.37 %). Whenever possible,
patients who relapsed or had a persistent tumor after
completing initial treatments received the salvage
treatments of intracavitary brachytherapy, surgery, or
further adjuvant chemotherapy.
MR imaging
Head and neck MRI scans covering the area from the
lower temporal lobe to the supraclavicular were
Table 1 The characteristics, staging categories, and treatment regimens of NPC patients
Characteristics All patients MSI MPM only LPM ITF
No. of patients 1197 283 (23.64 %)a 102 (8.52 %) 181 (15.12 %) 19 (1.59 %)
Male 905 (75.61 %) 224 (79.15 %) 77 (75.49 %) 147 (81.22 %) 14 (73.68 %)
Female 292 (24.39 %) 59 (20.85 %) 25 (24.51 %) 34 (18.78 %) 5 (26.32 %)
Median age (y) 46 46 46 46 46
Age range (y) 11-84 11-84 11-84 12-79 22-76
Pathological typesb
WHO type III 1134 (94.74 %) 270 (95.41 %) 97 (95.10 %) 173 (95.58 %) 16 (84.21 %)
WHO type II 51 (4.26 %) 8 (2.83 %) 2 (1.96 %) 6 (3.32 %) 3 (15.79 %)
WHO type I 12 (1.00 %) 5 (1.76 %) 3 (2.94 %) 2 (1.10 %) 0
Clinical Stagesc
Stage I 57 (4.76 %) 0 0 0 0
Stage II 314 (26.23 %) 11 (3.89 %) 6 (5.88 %) 5 (2.76 %) 0
Stage III 541 (45.20 %) 112 (39.57 %) 62 (60.79 %) 50 (27.62 %) 1 (5.26 %)
Stage IVa 223 (18.63 %) 137 (48.41 %) 30 (29.41 %) 107 (59.12 %) 16 (84.21 %)
Stage IVb 62 (5.18 %) 23 (8.13 %) 4 (3.92 %) 19 (10.50 %) 2 (10.53 %)
T classifications
T1 295 (24.64 %) 0 0 0 0
T2 225 (18.8 %) 12 (4.24 %) 7 (6.86 %) 5 (2.76 %) 0
T3 441 (36.84 %) 120 (42.40 %) 64 (62.75 %) 56 (30.94 %) 0
T4 236 (19.72 %) 151 (53.36 %) 31 (30.39 %) 120 (66.30 %) 19 (100 %)
N classifications
N0 170 (14.20 %) 50 (17.67 %) 22 (21.57 %) 28 (15.47 %) 6 (31.58 %)
N1 675 (56.39 %) 148 (52.30 %) 51 (50.00 %) 97 (53.59 %) 6 (31.58 %)
N2 290 (24.23 %) 62 (21.91 %) 25 (24.51 %) 37 (20.44 %) 5 (26.32 %)
N3a 26 (2.17 %) 8 (2.82 %) 0 8 (4.42 %) 0
N3b 36 (3.01 %) 15 (5.30 %) 4 (3.92 %) 11 (6.08 %) 2 (10.52 %)
Chemotherapy
Induction 919 (76.78 %) 257 (90.81 %) 93 (91.18 %) 164 (90.61 %) 19 (100 %)
Concurrent 466 (38.93 %) 114 (40.28 %) 30 (29.41 %) 84 (46.41 %) 3 (15.79 %)
Adjuvant 493 (41.19 %) 125 (44.17 %) 37 (36.27 %) 88 (48.62 %) 11 (57.89 %)
NPC = Nasopharyngeal carcinoma; MSI = Masticator space Involvement; MPM =Medial pterygoid muscle; LPM = Lateral pterygoid muscle; ITF = infra temporal fossa
aNumbers in parentheses are percentages
bThe 3rd edition of World Health Organization (WHO) classification of pathological feature in 2003
cStaging system and definitions of TNM classification were according to the seventh edition of the American Joint Committee on Cancer (AJCC) Classification [13]
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conducted on all enrolled patients according to accepted
protocols on a 1.5 T MR system (Signa Excite 1.5 T HD
Twin Speed, GE Healthcare, WI, USA) or a 3.0 T MR
system (Achieva 3.0 T, Philips Healthcare, Best,
Netherlands). Before any anti-tumor treatments, all
patients were subjected to five standard sequences as
follow: 1) axial T1-weighted imaging-fast spin echo
(T1WI-FSE) with the parameters of repetition time
(TR)/echo time (TE) = 550/9.2 ms, field of view
(FOV) = 36 cm × 36 cm, matrix = 160 × 160, slices = 36,
thickness = 6 mm, gap = 0 mm, number of excitations
(NEX) = 2; 2) axial proton density-weighted imaging
(PDWI) or T2-weighted imaging with short TI inver-
sion recovery (T2WI-STIR): TR/TE = 3200/70 ms,
FOV = 36 cm × 36 cm, matrix = 960 × 960, slices = 36,
thickness = 4 mm, gap = 0 mm, NEX = 4; 3) coronal
T2WI-STIR: TR/TE = 2,327/63 ms, FOV = 36 cm× 36 cm,
matrix = 160 × 160, slices = 18, thickness = 4 mm, gap =
0 mm, NEX = 2; 4) sagittal T1WI-FSE: TR/TE = 600/
9.2 ms, FOV = 36 cm× 36 cm, matrix = 160 × 160, slices =
18, thickness = 6 mm, gap = 0 mm, NEX = 2; 5) post-
contrast enhanced acquisition of axial T1WI-FSE with fat
suppression (fs): TR/TE = 1215/9.2 ms, FOV = 36 ×
36 mm, matrix = 160 × 160, slices = 36, thickness = 6 mm,
gap = 0 mm, NEX = 2. In the post-contrast acquisition, a
gadolinium-based agent (Gadopentetate dimeglumine,
Magnevist; Bayer Healthcare, Berlin, Germany) was intra-
venously injected at a rate of 1.5 ml/sec with a dose of
0.1 mmol per kilogram of the patient’s body weight
followed by a 20 ml saline flush. Among the sequences
listed above, axial orientation was perpendicular to C3,
and the coronal orientation was parallel to C3. The total
time for collecting a conventional MR scan was about 15
to 20 min.
All acquired MR images were reinterpreted independ-
ently by two radiologists specializing in head and neck
MRI and who had eight and ten years of experience,
respectively. Any disagreements were resolved by con-
sensus. The diagnostic criterion for MSI was as follow
(Fig. 1): primary tumor’s extension beyond the paraphar-
yngeal space and pterygopalatine fossa and the erosion
of the anatomical MS, which raises the signal intensity
on the PDWI or T2WI-STIR images and significantly
enhances the signal on the post-contrast T1WI-FSE im-
ages, both axial and coronal, in whole or in part and, at
the same time, presents the erosion or disappearance of
high signal intensity in the parapharyngeal space or pter-
ygopalatine fossa on T1WI-FSE images.
Follow-up and statistical analyses
The median follow-up time was 57 months (range from
7 to 105 months). Overall survival (OS) rate was calcu-
lated from the first day of diagnosis to the death date or
the last follow-up, local relapse-free survival (LRFS) to
the date of local relapse, regional relapse-free survival
(RRFS) to the date of regional relapse, and distant
metastasis-free survival (DMFS) to the date of distant
metastasis, respectively. All statistical analyzes were
conducted with the SPSS software (Version 18.0, Inc.,
Chicago, IL, USA). The frequency of different degrees of
MSI among different T-staging categories was analyzed
and compared by the Chi-square test. Survival curves
were analyzed by the Kaplan-Meier method and differ-
ences compared by the Log-Rank test. Cox regression
analysis was applied to evaluate the various prognostic
factors systematically in NPC patients. A two-tailed P
value < 0.05 was considered statistically significant.
Results
Patients with masticator space involvement
Using achieved MRI data, MSI were apparent in 283
cases (23.64 %), of which 102 (8.52 %) cases involved the
MPM only, and the other 181 (15.12 %) infiltrated both
the MPM and LPM. Furthermore, 19 (1.59 %) patients
Fig. 1 MR images of a 40-year old man with undifferentiated nonkeratinizing squamous cell nasopharyngeal carcinoma. MR images demonstrate
NPC’s involvement of the MPM and LPM (long arrow), and the temporal muscle (arrowhead) as well as pterygopalatine fossa(star), which present
a high signal intensity on axial PDWI image (a), a medium or low signal intensity on axial T1WI-TSE image (b), and an obvious enhancement on
axial contrast-enhanced T1WI-TSE image with fat suppression (c). (MRI = Magnetic resonance imaging; NPC = Nasopharyngeal carcinoma;
MPM =Medial pterygoid muscle; LPM = Lateral pterygoid muscle; PDWI = Proton density-weighted imaging; T1WI-TSE = T1 weighted
imaging-Turbo spin echo)
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with LPM erosion also affected the ITF (including 19
temporal muscle and 5 masseter muscle). The character-
istics, staging categories, and treatment regimens for
NPC patients with different degrees of MSI were de-
tailed in Table 1. Furthermore, a total of 271 (95.76 %)
patients were treated with platinum-based chemother-
apy, including induction in 73 (26.94 %), concurrent in 8
(2.95 %), adjuvant in 2 (0.74 %), induction-concurrent in
65 (23.98 %), induction-adjuvant in 82 (30.26 %),
concurrent-adjuvant in 4 (1.48 %), and induction-
concurrent-adjuvant in 37 (13.65 %).
The survival outcomes of patients with masticator space
involvement
For the entire group of 1197 patients, the 5-year OS,
LRFS, and DMFS rates were 81.7, 93.4, and 83.2 %, re-
spectively. Patients developed local recurrence, regional
recurrence, and distant metastasis in 79 (6.6 %), 52
(4.3 %), and 20 (16.8 %) cases, respectively. Only 20
(1.67 %) patients presented with both local and regional
recurrence, and 219 (18.3 %) ultimately died of the dis-
ease. As for patients with MSI, the 5-year OS, LRFS, and
DMFS rates were 71.7, 90.5, and 77.7 %, respectively,
and local recurrence, regional recurrence and distant
metastasis developed in 27 (9.5 %), 11 (3.9 %) and 63
(22.3 %) cases, respectively. And there were 80 (28.3 %)
who died by the ultimate follow-up, incluiding 61 dis-
tant metastasis or local-regional recurrences and 19
treatment-related complications. Furthermore, by compar-
ing the survival outcomes between different degrees of
MSI (only MPM, LPM, and ITF), the 5-year OS rates were
77.5, 68.5, and 63.16 %, LRFS rates were 95.1, 87.8, and
84.21 %, RRFS rates were 97.1, 95.6, and 89.47 %, and
DMFS rates were 80.4, 76.2, and 63.16 %, respectively.
And their corresponding local recurrence developed
in 5/102 (4.9 %), 22/181 (12.2 %), and 3/19 (36.84 %)
cases, respectively, regional recurrence developed in
3/102 (2.9 %), 8/181 (4.4 %), and 2/19 (10.53 %), re-
spectively, and distant metastasis developed in 20/102
(19.6 %), 43/181 (23.8 %), and 7/19 (36.84 %), re-
spectively. Interestingly, there were only 12 patients
identified as MSI alone (without extension to any T3
or T4 structures), and their OS, LRFS, RRFS, and
DMFS were much higher, at 83.3, 100, 100, and 91.7 %,
respectively.
The log-rank test showed that the survival outcomes
of patients with MSI were significantly worse than those
without involvement with regard to OS (71.7 vs. 84.8 %;
P < 0.001), LRFS (90.5 vs. 94.3 %; P = 0.011), and DMFS
(77.7 vs. 84.9 %; P = 0.002) but not for RRFS (96.1 vs.
95.5 %; P = 0.884) (Fig. 2). Besides, patients with tumors
involving the MPM only presented a higher LRFS
than those concurrently affecting the LPM (95.1 vs.
87.8 %; P = 0.027), even though they had a consistent
OS (77.5 vs. 68.5 %; P = 0.098), RRFS (97.1 vs. 95.6 %;
P = 0.459), and DMFS (80.4 vs. 76.2 %; P = 0.273;
Fig. 3). Patients with ITF erosion behaved a consistent
OS, LRFS, RRFS, and DMFS with those involving the
MPM and/or LPM (P > 0.05; Table 2 and Fig. 3).
The prognosis of patients with masticator space
involvement and different T-staging categories
As for the subgroup of patients with tumors involving
the MPM only, their 5-year OS and DMFS rates were
significantly worse than the rates of those classified as
T1 stage (P = 0.01; P = 0.008) and were more consistent
with a T3 or T4 stage tumor (P > 0.05), while the 5-year
LRFS rate was not significantly different from those clas-
sified as a T2 or T3 disease (P > 0.1) and higher than
those at T4 stage (P = 0.008, Fig. 4). When the tumor
concurrently invaded into the LPM or ITF, however, pa-
tients had worse 5-year OS and LRFS rates than those
classified as stage T1, T2, or T3 (P < 0.05). These rates
were more consistent with a T4 disease (P > 0.1). More-
over, their 5-year RRFS rates were more consistent with
those classified as T2, T3, or T4 stage (P > 0.1), and their
5-year DMFS rates were more consistent with stage T4
(P > 0.1; Fig. 4; Table 2). Nevertheless, among patients
classified as a T2, T3 or T4 stage disease, respectively,
MSI did not significantly affect their OS, LRFS, RRFS,
and DMFS (P > 0.05). But for the subgroup of patients
composed of T3 and T4 stages, tumors involving the
MPM only presented a higher LRFS than those concur-
rently affecting the LPM (P = 0.035; Fig. 5) even though
they had a similar OS, RRFS, and DMFS (P = 0.070,
P = 0.504, and P = 0.264; respectively). Whereas, pa-
tients with the concurrent erosion of ITF remained a
consistent OS, LRFS, RRFS, and DMFS with those
infiltrating the MPM and/or LPM (P > 0.05; Fig. 5).
In the general group, most patients with MSI concur-
rently involved structures that earned T3 and T4 classifi-
cations (271/283, 95.76 %) while only a small proportion
of cases without MSI did (406/914, 44.42 %). In the sub-
group of patients with different degrees of MSI, a major-
ity of tumors involving the MPM only had concurrent
erosions of T3-stage structures, while most of those
with LPM involvement concurrently infiltrated T4-
stage structures, and 100 % of subgroup patients with
ITF erosion affected other T4-stage structures concur-
rently (see Table 3). Table 3 lists the frequencies of
concurrent erosions at other sites between different
degrees of MSI.
The frequencies of concurrent erosion at other T3 or
T4-stage structures in the subgroup of patients with
MPM involvement were mostly lower than in the
subgroup of LPM extension, particularly at the ptery-
gopalatine fossa (25.49 vs. 49.17 %, P < 0.05), para-
nasal sinus (19.61 vs. 38.67 %, P < 0.05), cavernous sinus
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(20.59 vs. 48.61 %, P < 0.05), foramen (11.76 vs. 33.15 %,
P < 0.05), oval foramen (42.16 vs. 60.77 %, P < 0.05),
meninges (24.49 vs. 44.75 %, P < 0.05) and cranial nerves
(6.86 vs. 27.07 %, P < 0.05). And the majority of these
above frequencies were relatively lower than in patients
with ITF invasion (see Table 3).
Multivariate analyses of prognostic factors
Cox regression analysis was employed by multivariate
analyses to systematically evaluate how various prognos-
tic factors affected patients’ survival outcomes. The
following factors were taken into the calculation in the
Cox regression analysis: gender, histopathology, age
(≥50 years vs. <50 years), T classification (T1-2 vs. T3-4),
N classification (N0-1 vs. N2-3), clinical staging (Stage I,
II vs. III, IV), parapharygeal space extension, skull base
erosion, paranasal sinus erosion, degrees of MSI (no
MSI vs. MPM only vs. LPM vs. ITF), pterygopalatine
fossa infiltration, perineural spread, intracranial invasion,
and chemotherapy. As a result, degrees of MSI were
demonstrated to be an independent prognostic factor for
the OS significantly (P = 0.036) but not for the LRFS
(P = 0.526), RRFS (P = 0.539), and DMFS (P = 0.401),
respectively. Other insignificant prognostic factors for
the OS, LRFS, RRFS, and DMFS included the variables of
gender, histopathology, parapharygeal space extension,
skull base erosion, paranasal sinus erosion (P > 0.05). On
the other hand, independent prognostic factors for the OS
included age, N classification, pterygopalatine fossa
infiltration, perineural spread, and intracranial inva-
sion (P < 0.05). For the LRFS, the independent factors
were age, N classification, pterygopalatine fossa infil-
tration, perineural spread, and intracranial invasion
(P < 0.05). Only N classification and perineural spread
were demonstrated as independent factors for the
RRFS (P < 0.05), while the independent factors for the
DMFS were identified as age, T classification, N clas-
sification, perineural spread, and chemotherapy (P < 0.05,
see Table 4).
Discussion
Our present results indicate that NPCs with MSI had a
worse OS, LRFS, and DMFS than those without involve-
ment. Even that the degree of MSI was not a significant
prognostic factor for the LRFS, RRFS and MDFS, it was
demonstrated as the independent prognostic factor for
patients’ overall survival rates. Furthermore, the sub-
group of patients with an erosion of the lateral mastica-
tor space (i.e., LPM and ITF) presented a poorer
prognosis (more consistent with T4 stage) than those
Fig. 2 Survival curves compared between NPC patients with and without MSI. a Overall survival rate; b Local relapse-free survival rate; c Regional
relapse-free survival rate; d Distant metastasis-free survival rate. (NPC = Nasopharyngeal carcinoma; MSI = Masticator space involvement)
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affecting the MPM only (consistent with T3 stage). Thus,
NPC with the lateral MSI extension was recommended
to be classified as a higher T-stage category.
Anatomical MS is enclosed by the superficial layer of
the deep cervical fascia, and this space contains not only
the masticatory muscles but also the mandible and the
cranial nerve of V3 [23, 24]. Thus, imaging modalities
(i.e., CT, MRI) are always employed to characterize the
complex anatomical features of MS. In particular, MRI is
superior to CT in the diagnosis of MSI, with a higher
tissue contrast and sensitivity, which allows us to stage a
large number of NPC patients more efficiently. It is in-
teresting that MRI diagnosed a higher frequency of MSI
in our present study than in previous studies conducted
by Tang et al. [9] (23.64 vs. 19.7 %) and Zhang et al. [11]
(23.64 vs. 20.2 %), even for the subgroups of tumor in-
volving the MPM only (23.64 vs.18.70 %; 23.64 vs.
20.00 %; respectively) and the LPM (15.12 vs. 10.00 %;
15.12 vs. 8.40 %; respectively). In another previous study,
Sze et al. [10] observed a much higher frequency for
both MSI (61.00 %) and the erosion of MPM only
(43.84 %), however, that of LPM invasion was relatively
lower at 11.96 %. Moreover, all patients with MSI in this
study had tumors invading the MPM, and any tumor
with erosion of LPM or ITF also concurrently affected
the MPM, which is quite different from the previous
studies [9–11].
In the staging of NPC, MSI has always been taken as a
key indicator for stage T4 classification, which reflects
the observed risk for distant metastasis and tumor recur-
rence in patients treated for non-metastatic NPC [9, 25].
When surveyed, however, the prognostic value of MSI
varies considerably among different previous studies.
Tang et al.’s study suggested MSI predicted survival out-
comes that were consistent with a T4 disease and argued
that the levels of MSI did not correlate with patient’s OS
and LRFS [9]. In contrast, Sun et al. [26] and Zhang
et al. [11] both claimed different patterns of MSI pre-
sented distinct survival outcomes, and the LPM erosion
correlated with a T4 stage while the involvement of only
MPM correlated with a T2 stage [11], which agrees with
our results. On the other hand, Chen et al. demonstrated
that in the subgroup of patients with the T4 stage, tu-
mors involving the MS (T4a) presented a higher OS and
DMFS rates than those involving other T4 structures
(T4b), while their LRFS rates were not significantly dif-
ferent [25]. Pan et al.’s results also suggest a subset of
patients with MSI should be up-staged to T3 or T4 even
Fig. 3 Survival curves compared between subgroups of NPC patients suffering from different degrees of MSI. a Overall survival rate; b Local
relapse-free survival rate; c Regional relapse-free survival rate; d Distant metastasis-free survival rate. (NPC = Nasopharyngeal carcinoma;
MSI = Masticator space involvement; MPM =Medial pterygoid muscle; LPM = Lateral pterygoid muscle; ITF = infratemporal fossa)
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though the involvement of MPM and LPM was not
associated with the poor prognosis linked to other
structures [12].
MSI has been regarded as a significant prognostic fac-
tor for the prognosis of NPCs [9], and under most cir-
cumstances the extent of involvement strictly correlated
with the survival outcomes we measured. Our present
results also showed that MSI, especially the lateral MSI
extension, did bring a relatively poorer survival outcome
and the degree of MSI was demonstrated as an inde-
pendent prognostic factor for the OS even though it was
not for the LRFS, RRFS and DMFS. In addition, tumors
with lateral MSI extension always came with concurrent
involvement at other sites that, on their own, could stage
the tumors as T3 or T4 classification. (These regions as-
sociate with T4 tumors include the pterygopalatine fossa,
V2 or V3, or orbit and are independent factors for a
poor prognosis.) As shown in Table 3, frequencies of
concurrent erosion of other T3 or T4 structures were
higher in patients with MSI than in those without MSI.
Thus, the higher rates of concurrently involving the fur-
ther T-stage structures may result in worse survival out-
comes for patients with MSI. Moreover, in this study,
only a few patients were finally proven to have MSI
alone (no involvement of other T3 or T4 structures as
well), and these patients always displayed a relatively
better survival outcome which was consistent with the
T1 or T2 stages, which agrees with Sze et al.’s study
[10]. On the other hand, even though whether or not
the tumor involved the MPM or LPM had no effects on
the patients’ OS and DMFS, tumors involving the MPM
only were linked to a higher LRFS than those infiltrating
the LPM. However, NPCs involving the LPM (as op-
posed to the MPM) always tended to more frequently
affect other sites of the T4 stage, which always linked to
an aggressive disease and poor prognosis (Table 3). As
for patients classified as different T-staging categories,
those with tumor erosions of LPM or ITF used to affect
concurrently other structures that elicited an equivalent
or higher T stage. In this sense, when evaluating the
prognostic value of MSI in NPC patients, these sites of
concurrent involvement should be weighted and bal-
anced heavily.
Generally, NPC originates from the nasopharyngeal
mucosa, in a stepwise fashion, moving laterally into the
parapharyngeal space and then spreading directly into
the anatomical MS. Moreover, tumors invading the pter-
ygopalatine fossa also find a route to spread into masti-
cator space indirectly. Therefore, among patients with
MSI, all of them had concurrent involvement in the
parapharyngeal space, and some even displayed concur-
rent erosion of the pterygopalatine fossa with a per-
centage of 25.49 vs. 49.17 % for MPM only vs. LPM
(P < 0.05). Furthermore, it was reported that a tumor’s
extension to parapharyngeal space, pterygopalatine
fossa, and masticator space was always associated with
a higher risk of distant metastasis and tumor recur-
rence [26–28]. Tang et al. suggested MSI would increase
the risk of distant metastasis and tumor recurrence and
should be categorized as a T4 tumor [9]. However, these
studies did not evaluate the importance of MSI itself,
so the negative impacts on the OS, LRFS and DMFS
(P < 0.05) can be attributed to the fact that tumors
that spread to the MS generally also affect other
structures associated with more aggressive diseases.
Sze et al. [10] believed that NPC patients with MSI
alone displayed a better survival outcome, which
agrees with this study. Since the pterygopalatine fossa
contains the maxillary division of the trigeminal nerve
(V2), a tumor’s spread into this region should be ex-
pected to increase the risk of V2 infiltration and
worsen the survival outcomes. In this study, the fre-
quency of tumors concurrently infiltrating V2 among
subgroup patients with the involvement of MPM only
vs. LPM was 11.76 vs. 33.15 %, respectively. Similarly,
the mandibular division of the trigeminal nerve (V3)
runs through the interval space lying between the
MPM and LPM. When tumors concurrently involved
the LPM, the risk for the infiltration of V3 would
dramatically increase. In the present results, patients
Table 2 Comparison of survival outcomes between different
degrees of masticatory space involvement and T-categories
Log rank (Mantel-Cox) P-value OS LRFS RRFS DMFS
MPM only vs. T1 0.010 0.114 0.417 0.008
T2 0.056 0.976 0.333 0.250
T3 0.434 0.814 0.612 0.742
T4 0.097 0.008 0.147 0.184
LPM 0.098 0.027 0.459 0.273
ITF 0.151 0.057 0.077 0.058
LPM vs. T1 <0.001 <0.001 0.041 <0.001
T2 <0.001 0.005 0.779 0.007
T3 <0.001 0.001 0.714 0.057
T4 0.910 0.482 0.404 0.861
MPM only 0.098 0.027 0.459 0.273
ITF 0.560 0.553 0.161 0.135
ITF vs. T1 <0.001 <0.001 0.005 <0.001
T2 0.004 0.033 0.257 0.004
T3 0.037 0.034 0.124 0.020
T4 0.572 0.886 0.412 0.210
MPM only 0.151 0.057 0.077 0.058
LPM 0.560 0.553 0.161 0.135
MPM medial pterygoid muscle, LPM lateral pterygoid muscle, ITF infra temporal
fossa, OS overall survival, LRFS local relapse-free survival, RRFS regional
relapse-free survival, DMFS Distant metastasis-free survival
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with the LPM erosion owned a higher rates of con-
current V3 infiltration than those with MPM involvement
(60.77 vs. 42.16 %; P < 0.05). Therefore, these perineural
and intracranial spreads that were demonstrated as signifi-
cant prognostic factors in the multivariate analysis would
primarily result in a poorer LRFS for patients with LPM
involvement. Nevertheless, thanks to the ever-improving
local control rate afforded by IMRT, outcomes are im-
proving even for patients harboring aggressive tumors.
Even though MSI is known to worsen NPC’s survival
outcomes, its T-staging categories are always inconsist-
ent and controversial [9–13]. It is observed that NPC pa-
tients with the involvement of MPM only showed a
consistent OS and LRFS with a T2 or T3 diagnosis
whereas those concurrently affected the LPM were more
consistent with a T4 disease. However, only 5/225
(2.22 %) of T2 cases and 56/441 (12.70 %) of T3 cases
had tumors infiltrating the LPM while the frequency was
much higher for T4 cases at 120/236 (50.84 %) (Table 1).
Thus, NPCs involving the LPM more often concurrently
spread into the deeper structures (i.e., pterygopalatine
fossa, cranial nerves, and intracranial structures), which
obviously worsen the survival outcomes. Chen et al. [25]
asserted NPC patients categorized as the T4a subclassifi-
cation (with involvement of MS) had a significantly
higher OS (P = 0.033) and DMFS (P = 0.036) than those
of the T4b subclassification (without involvement of
MS). Sze et al. also indicated that NPCs infiltrating the
MPM and/or LPM alone (without invasion to other T3
and T4 structures) always owned a better survival out-
come and should be staged as T2 diseases [10]. (That is
unless the tumor has invaded structures that, in their
own right, render a classification of T3 or T4.) Our
present results agree with these assertions.
Among MSI patients, only 12 (4.24 %) cases involved
the MS alone (without involvement of any T3 or T4
structures), including 7 cases that invaded the MPM
only and other 5 that affected both the MPM and LPM,
yielding a much smaller proportion of only 1 % among
the entire group of NPC patients. Tang et al. reported a
similar lower frequency of MSI alone (2.2 %) [9] that
agrees with the present results. However, those patients
with MSI alone were clearly demonstrated to diaplay a
dramatically better survival outcome among which no
local or regional recurrence was observed by the ultim-
ate follow-up. Therefore, NPC tumors with MSI alone
Fig. 4 Survival curves compared between subgroups of NPC patients suffering from different degrees of MSI and different T-stage categories. a Overall
survival rate; b Local relapse-free survival rate; c Regional relapse-free survival rate; d Distant metastasis-free survival rate. (NPC = Nasopharyngeal
carcinoma; MSI = Masticator space involvement; MPM =Medial pterygoid muscle; LPM = Lateral pterygoid muscle; ITF = infratemporal fossa;
OS = Overall survival; LRFS = Local relapse-free survival; DMFS = Distant metastasis-free survival; RRFS = Regional relapse-free survival)
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Fig. 5 Survival curves compared between different degrees of MSI among NPC patients composed of T3 and T4 stages. a Overall survival
rate; b Local relapse-free survival rate; c Regional relapse-free survival rate; d Distant metastasis-free survival rate. (MSI = Masticator space
involvement; NPC = Nasopharyngeal carcinoma; MPM =Medial pterygoid muscle; LPM = Lateral pterygoid muscle; ITF = infratemporal fossa;
NPC = Nasopharyngeal carcinoma)
Table 3 Frequencies of concurrently involving sites for NPCs with different degrees of MSI
Concurrent involvement sites no MSI MSI MPM only LPM ITF
No. of patients 914 283 102 181 19
Nasal fossa 106 (11.60 %)a 75 (26.50 %) 25 (24.51 %) 50 (27.62 %) 6 (31.58 %)
Pre-vertebral muscles 171 (18.71 %) 126 (44.52 %) 36 (35.29 %) 90 (49.72 %) 11 (57.89 %)
Oropharynx 2 (0.22 %) 19 (6.71 %) 4 (3.92 %) 15 (8.29 %) 1 (5.26 %)
Pterygopalatine fossa 96 (10.50 %) 115 (40.64 %) 26 (25.49 %) 89 (49.17 %) 15 (78.95 %)
Paranasal sinuses 76 (8.32 %) 90 (31.80 %) 20 (19.61 %) 70 (38.67 %) 10 (52.63 %)
Skull base bones 387 (42.34 %) 267 (94.35 %) 93 (91.17 %) 174 (96.13 %) 19 (100.00 %)
Oval foramen 55 (6.02 %) 153 (54.06 %) 43 (42.16 %) 110 (60.77 %) 12 (63.16 %)
Foramen 25 (13.13 %) 72 (25.44 %) 12 (11.76 %) 60 (33.15 %) 12 (63.16 %)
Orbit 4 (0.44 %) 11 (3.89 %) 1 (0.98 %) 10 (8.39 %) 2 (10.53 %)
Cranial nerves 33 (3.61 %) 58 (20.49 %) 7 (6.86 %) 51 (28.18 %) 9 (47.37 %)
Cavernous sinus 63 (6.89 %) 109 (38.52 %) 21 (20.59 %) 88 (48.61 %) 8 (42.11 %)
Meninges 47 (5.14 %) 107 (37.81 %) 26 (24.49 %) 81 (44.75 %) 10 (52.63 %)
NPC nasopharyngeal carcinoma, MSI masticaor space involvement, MPM medial pterygoid muscle, LPM lateral pterygoid muscle, ITF infratemporal fossa
aNumbers in parentheses are percentages
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may be more reasonable to classify as a T2-stage as was
suggested by Sze et al. [10]. In contrast, 5-year OS,
LRFS, and DMFS rates of patients with erosions of ITF
were relatively poorer at 63.16, 84.21, and 63.16 % re-
spectively, and different editions of the AJCC staging
system have identified the ITF as the lateral part of ana-
tomical MS and thus, categorised a tumor’s spread into
this region as a T4 disease [13]. Even though they were
not significantly different from those with MPM and/or
LPM infiltration, the frequencies of temporal and
masseter muscle abnormalities were both much lower
in the entire group (1.09 and 0.33 %, respectively)
and may be insufficient in statistical analysis, which
also agrees with Tang et al.’s study [9] Furthermore, a
tumor’s lateral extension into ITF always tended to
concurrently affect other sites that rendered a T4
classification (i.e., the cavernous sinus, cranial nerves,
and meninges). Therefore, the lateral extension of
MSI (i.e., LPM and ITF) might sharply worsen pa-
tient’s survival outcomes and should be classified as
higher T-stage categories as was recommended by the
2008 Chinese staging system.
The limitation of this present study is that for such a
retrospective study, the sample size was relatively insuffi-
cient, so another study with a larger sample size is
needed. Furthermore, this study was conducted with data
from a single medical center. Thus, a prospective study of
multiple centers should derive a more unbiased result.
Conclusions
Multivariate analyses indicate that the degree of MSI is a
significant prognostic factor for the OS of NPCs treated
with IMRT, NPCs with tumors infiltrating the LPM and
ITF present poorer prognostic outcomes than those af-
fected the MPM only and T3-stage disease, and those
with MSI alone always associate with relatively higher
survival rates. Thus, it is highly recommended that tu-
mors with MSI alone be classified under the T2-stage
while the lateral MSI extension (LPM and ITF) be classi-
fied as higher T-staging categories in the next revision of
T-staging for NPCs.
Abbreviations
NPC: Nasopharyngeal carcinoma; IMRT: Intensity-modulated radiation
therapy; MRI: Magnetic resonance imaging; MS: Masticator space;
Table 4 Multivariate analysis of prognostic factors in IMRT-treated NPC patients
Endpoint Variable P-value Odds ratioa
Death N classification (N0–1 vs. N2–3) <0.001 1.569 (1.281, 1.922)
Age (≥50 y vs. < 50 y) <0.001 2.653 (2.012, 3.498)
Pterygopalatine fossa infiltration 0.005 0.555 (0.368, 0.837)
Degrees of MSI (no MSI vs. MPM only vs. LPM vs. ITF) 0.036 1.233 (1.014, 1.499)
Intracranial invasion 0.010 22.052 (1.860, 261.444)
Perineural spread 0.004 1.671 (1.073, 2.600)
Local failure T classification (T1–2 vs. T3–4) 0.248 1.301 (0.833, 2.034)
N classification (N0–1 vs. N2–3) 0.033 1.437 (1.031, 2.004)
Age (≥50 y vs. < 50 y) 0.036 1.613 (1.030, 2.525)
Pterygopalatine fossa infiltration 0.017 1.961 (1.130, 3.405)
Degrees of MSI (no MSI vs. MPM only vs. LPM vs. ITF) 0.526 0.906 (0.668, 1.229)
Intracranial invasion 0.020 32.712 (3.459, 309.393)
Perineural spread 0.006 2.474 (1.302, 4.699)
Regional failure N classification (N0–1 vs. N2–3) 0.015 1.752 (1.117, 2.746)
Degrees of MSI (no MSI vs. MPM only vs. LPM vs. ITF) 0.539 0.873 (0.566, 1.347)
Perineural spread 0.049 2.477 (1.004, 6.112)
Distant failure T classification (T1–2 vs. T3–4) 0.037 1.431 (1.022, 2.004)
N classification (N0–1 vs. N2–3) <0.001 1.769 (1.412, 2.217)
Age (≥50 y vs. < 50 y) 0.014 1.431 (1.074, 1.906)
Perineural spread 0.012 1.871 (1.150, 3.042)
Degrees of MSI (no MSI vs. MPM only vs. LPM vs. ITF) 0.401 1.093 (0.888, 1.345)
Chemotherapy 0.048 1.838 (1.006, 3.359)
NPC nasopharyngeal carcinoma, IMRT intensity modulated radiation therapy, MSI masticator space involvement, MPM medial pterygoid muscle, LPM lateral
pterygoid muscle, ITF infratemporal fossa
aNumbers in parentheses give 95 % confidence intervals
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